Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin)

Breast Journal

Volumn 13, Issue 1, 2007, Pages 72-75

  Gonzalez, Ricardo J ^a   Buzdar, Aman U ^a   Fraser Symmans, W ^a   Yen, Tina W ^a   Broglio, Kristine R ^a   Lucci, Anthony ^a   Esteva, Francisco J ^a   Yin, Guosheng ^a   Kuerer, Henry M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Ductal carcinoma in situ; Neoadjuvant systemic therapy; Trastuzumab (Herceptin)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TRASTUZUMAB;

ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOMA IN SITU; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ERBB-2; RESEARCH DESIGN;

EID: 33845974062     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2006.00366.x     Document Type: Article

References (18)

1. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995;76:1197-2000.
2. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004;96:443-48.
3. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993-2000.
4. Esserman L, Sepucha K, Ozanne E, Hwang ES. Applying the neoadjuvant paradigm to ductal carcinoma in situ. Ann Surg Oncol 2004;11(1 Suppl.):28S-36S.
5. Hwang ES, Esserman L. Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results. Ann Surg Oncol 2004;11(1 Suppl.):37S-43S.
6. Buzdar AU, Hunt KK, Smith TL, et al. Significantly higher pathological complete remission rate following neoadjuvant therapy with trastuzumab and anthracycline-containing chemotherapy: initial results of a randomized trial in operable breast cancer with Her2 positive disease. J Clin Oncol 2004;23:7S.
7. Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004;10:5650-55.
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
9. Benz CC, Scott GK, Sarup JC. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transferred with HER-2/neu. Breast Cancer Res Treat 1992;24:85-89.
10. Bijker N, Peterse JL, Duchateau L, et al. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 2001;84:539-44.
11. Lewis GD, Figari I, Fendly B, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255-63.
12. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-904.
13. Yen TW, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 2005;200:516-26.
14. Cole BF, Gelber RD, Gelber S, et al. Polychemotherapy form early breast cancer: an overview of the randomized clinical trials with quality-adjusted survival analysis. Lancet 2001;358:277-86.
15. Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2003;2:1113-20.
16. Rodrigues L, Mansi J, Griffiths J. Radiation enhances the antitumor effect of Herceptin on c-neu/HER2 mammary carcinomas in transgenic oncomice. Proc Am Assoc Cancer Res 2003;132a.
17. Allred D, Bryant J, Land S, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP B-24. Presented at the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 11-14, 2002.
18. Collins LC, Schnitt SJ. HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Mod Pathol 2005;18:615-20.